Topic: Diabetes.
Destination: JDRF is committed to accelerating the development of therapies that can complement insulin (i.e., adjunctive therapies) to improve glucose and metabolic outcomes in people with type 1 diabetes (T1D). To this end, they invite applications that propose (1) clinical trials to evaluate glucometabolic therapies in people with T1D or (2) mechanistic clinical studies to advance our knowledge of glucometabolic control in T1D toward the goal of future therapy development.
Budget: $1,000,000-2,000,000.
Duration: 2-3 years.
Fill out the form below to receive more information: